Twin Anemia Polycythemia Sequence (TAPS)

Twin Anemia Polycythemia Sequence (TAPS): A Comprehensive Guide

Twin Anemia Polycythemia Sequence (TAPS) is a rare but serious complication affecting monochorionic twin pregnancies. This condition represents a chronic form of unbalanced feto-fetal transfusion that occurs through microscopic placental connections called anastomoses. Understanding TAPS is critical for expectant parents and healthcare providers managing pregnancies with monochorionic placentation. This comprehensive guide explains the condition’s mechanisms, diagnostic approaches, available treatments, and potential outcomes.

What is Twin Anemia Polycythemia Sequence?

Twin Anemia Polycythemia Sequence is a complication of monochorionic twin pregnancies characterized by hemoglobin discordance between the two fetuses. In this condition, one twin (the donor) develops anemia—a deficiency in red blood cells—while the other twin (the recipient) develops polycythemia, an excess of red blood cells. Unlike its related condition, Twin-Twin Transfusion Syndrome (TTTS), TAPS occurs without the characteristic amniotic fluid abnormalities that define TTTS, making it a distinct clinical entity.

The fundamental problem in TAPS involves placental vascular anatomy. The condition develops through small-diameter arteriovenous anastomoses in the placental tissue without the balancing arterioarterial anastomoses that would normalize blood flow between twins. This vascular configuration creates a chronic, slow transfusion from the donor twin to the recipient twin, gradually shifting hemoglobin levels over time.

Incidence and Occurrence

TAPS occurs in approximately 3 to 5% of spontaneous monochorionic twin pregnancies. Additionally, TAPS can develop iatrogenically following incomplete laser surgery for Twin-Twin Transfusion Syndrome, occurring in 2% to 16% of post-laser cases. This means that some pregnancies that undergo treatment for TTTS may subsequently develop TAPS as a secondary complication. Understanding these statistics helps clinicians identify at-risk populations and implement appropriate monitoring protocols.

How TAPS Develops

TAPS develops gradually through chronic unbalanced transfusion across the entire second and third trimester of pregnancy. The condition is progressive in nature, typically worsening as pregnancy advances, though in some cases it may be initially mild and even resolve spontaneously. The slow nature of TAPS differs markedly from the acute hemodynamic changes seen in TTTS, which often develops more rapidly and with more dramatic physiologic consequences.

Diagnosis of TAPS

Diagnostic Criteria

Accurate diagnosis of TAPS relies on specific ultrasound measurements and established diagnostic criteria. The primary diagnostic tool involves Doppler measurement of the fetal middle cerebral artery peak systolic velocity (MCA-PSV). A diagnosis of TAPS is confirmed when MCA-PSV measurements meet the following criteria:

• MCA-PSV in the anemic donor twin is ≥1.5 multiples of the median (MoM)
• MCA-PSV in the polycythemic recipient twin is ≤0.8 MoM
• Alternatively, MCA-PSV discordance of ≥1 MoM between twins can support the diagnosis

Importantly, in TAPS the amniotic fluid index (AFI) remains within normal limits, distinguishing it from TTTS where polyhydramnios and oligohydramnios are characteristic findings. This distinction is crucial for accurate diagnosis and appropriate management planning.

Timing of Diagnosis

TAPS typically develops across the entire second and third trimester, with diagnosis occurring at a median gestational age of approximately 27 weeks. Early recognition through regular monitoring of monochorionic twin pregnancies allows for timely intervention when necessary.

Staging System for TAPS

The Leiden staging system provides a framework for assessing TAPS severity and guiding treatment decisions. This classification system helps categorize cases from mild to severe based on ultrasound findings and fetal hemodynamic parameters. Stages range from mild disease with increased MCA-PSV in the anemic donor and decreased MCA-PSV in the recipient, to severe disease associated with critical Doppler findings, hydrops fetalis, or single twin demise.

Treatment Options for TAPS

Conservative Management

Expectant management remains appropriate for stage 1 and stage 2 TAPS cases. This approach involves close monitoring with regular ultrasound examinations, typically scheduled weekly once diagnosis is established. For stage 1 and 2 disease, delivery is generally indicated before 37 weeks gestation if TAPS persists beyond 32 weeks, as the risk of complications increases with advancing gestational age.

Intrauterine Transfusion (IUT)

Intrauterine blood transfusion represents an active intervention option for TAPS management. This procedure involves transfusing the anemic donor twin with packed red blood cells to increase hemoglobin levels. When combined with partial exchange transfusion in the recipient twin, this approach can effectively prolong pregnancy and reduce neonatal complications. Recent data demonstrates that donor transfusion followed by partial exchange in the recipient can extend pregnancy duration by a median of 5.6 weeks from initial procedure to delivery, while potentially obviating the need for neonatal transfusion.

Fetoscopic Laser Surgery

Fetoscopic laser ablation represents another intervention strategy, particularly for stage 3 and stage 4 disease. This procedure involves identifying and ablating the placental vascular connections responsible for the transfusion imbalance. Solomon laser technique is one approach used in this procedure. Laser surgery aims to separate the placental circulations and halt the ongoing transfusion process.

Preterm Delivery

In many TAPS cases, especially those with severe disease or when other interventions are not feasible, preterm delivery becomes the primary management strategy. Delivery decisions must balance the risks of prematurity against the ongoing complications of TAPS in utero. The timing of delivery is individualized based on disease severity, twin stability, and facility capabilities.

Selective Feticide and Pregnancy Termination

In selected severe cases, particularly when one twin has experienced significant deterioration or demise, selective reduction of the affected twin may be considered. Pregnancy termination remains an option for families facing severe diagnosis with poor prognosis.

Comparison: TAPS vs. TTTS

Complications and Outcomes

Fetal and Neonatal Risks

TAPS carries significant risks for both twins. Spontaneous fetal demise occurs in 5% to 11% of TAPS pregnancies, with donor twins at higher risk (8% to 18%) compared to recipients (2% to 5%). The anemic donor twin faces particular vulnerability to in-utero demise, while the polycythemic recipient risks complications from elevated hemoglobin levels and increased blood viscosity.

Long-term Neurodevelopmental Effects

Severe long-term neurodevelopmental impairment occurs in approximately 9% of TAPS survivors. Notably, donor twins face increased risk for cognitive impairment and hearing problems, with an incidence of 15% in donor twins. These long-term sequelae underscore the importance of early diagnosis, appropriate intervention, and close neonatal follow-up.

Monitoring and Follow-up

Once TAPS diagnosis is established, intensive monitoring becomes essential. Weekly ultrasound examinations allow assessment of MCA-PSV values, amniotic fluid volumes, fetal growth, and signs of hydrops or cardiac compromise. For cases managed conservatively, fetal echocardiography may be performed to evaluate cardiac function. Low-dose aspirin continuation may be recommended based on individual clinical circumstances. Careful timing of delivery, typically between 34 and 37 weeks for uncomplicated cases, balances the risks of prematurity against ongoing in-utero complications.

Current Research and Treatment Advances

The optimal treatment approach for TAPS remains under investigation. An international multicenter randomized trial (the TAPS trial) is currently evaluating different management strategies to establish evidence-based guidelines. Recent case series demonstrate that combined intrauterine transfusion with partial exchange transfusion can effectively extend pregnancy while reducing neonatal transfusion requirements. These advances suggest promising new directions for TAPS management, though further research is needed to establish clear clinical indications and protocols.

When to Seek Specialist Care

Families diagnosed with TAPS should seek consultation with fetal medicine specialists experienced in managing complex twin pregnancies. Specialized centers offering advanced diagnostic imaging, fetoscopic surgery capabilities, and intrauterine transfusion expertise provide comprehensive care options. Johns Hopkins Medicine and similar tertiary centers maintain specialized fetal therapy programs equipped to manage TAPS with all available treatment modalities.

Frequently Asked Questions (FAQs)

Q: Can TAPS be prevented?

A: While TAPS cannot be prevented entirely, early monitoring of monochorionic twin pregnancies allows for prompt diagnosis and timely intervention, which can improve outcomes and reduce complications.

Q: What is the difference between spontaneous TAPS and post-laser TAPS?

A: Spontaneous TAPS occurs naturally in 3-5% of monochorionic twins. Post-laser TAPS develops after treatment for TTTS in 2-16% of cases, making it an iatrogenic complication of surgical intervention.

Q: How often should twins with TAPS be monitored?

A: Once TAPS is diagnosed, weekly ultrasound monitoring is recommended to assess disease progression, MCA-PSV values, and signs of deterioration requiring intervention.

Q: Can mild TAPS resolve on its own?

A: Yes, in some cases mild TAPS may initially resolve spontaneously. However, the condition is typically progressive, and expectant management requires close monitoring with readiness for intervention.

Q: What are the long-term developmental risks for TAPS survivors?

A: Approximately 9% of TAPS survivors experience severe neurodevelopmental impairment. Donor twins face higher risk for cognitive impairment and hearing problems (15%), requiring careful pediatric follow-up and developmental assessment.

Q: Is intrauterine transfusion safe for TAPS treatment?

A: Intrauterine transfusion combined with partial exchange transfusion has demonstrated safety and efficacy in extending pregnancy duration and reducing neonatal complications in TAPS cases, though it requires specialized expertise.

Similar Articles

Alarming Rise in Self-Harm in Young People

Alarming Rise in Self-Harm in Young People

Skin Signs Of Non-Accidental Injury: Expert Guide For Clinicians

Lichen Simplex Of The Scrotum: Diagnosis And Treatment

Labial Adhesion In Prepubertal Girls: What Parents Need To Know

Thrush In Men: 5 Signs, Causes, And Treatment Options

Author

medha deb

 

Medha Deb is an editor with a master's degree in Applied Linguistics from the University of Hyderabad. She believes that her qualification has helped her develop a deep understanding of language and its application in various contexts.

Read full bio of medha deb